Previous 10 | Next 10 |
2023-03-21 13:17:27 ET Paratek Pharmaceuticals ( NASDAQ: PRTK ) is up 20% in Tuesday afternoon trading amid a report that the biopharma is a takeout target. Betaville Intelligence is reporting that those familiar with the situation say a private equity firm is the ...
2023-03-16 14:42:30 ET Paratek Pharmaceuticals press release ( NASDAQ: PRTK ): Q4 GAAP EPS of -$0.13 misses by $0.23 . Revenue of $75.6M (+137.7% Y/Y) beats by $12.13M . Shares -26% . Paratek also announced its full-year 2023 revenue guidance, which i...
2023-03-16 14:14:06 ET Paratek Pharmaceuticals, Inc. (PRTK) Q4 2022 Earnings Conference Call March 16, 2023, 08:30 AM ET Company Participants Sarah Higgins - VP, Finance, and Principal Accounting Officer Evan Loh - CEO Adam Woodrow - President and Chief Commercia...
2023-03-16 11:17:51 ET Paratek Pharmaceuticals ( NASDAQ: PRTK ) stock fell ~25% on Thursday after the company's FY23 revenue outlook was seen below estimates. GAAP EPS was -$1.17, compared to -$1.22 in Q4 2021. Total revenue grew +137.7% Y/Y to $75.6M and also b...
2023-03-16 10:03:57 ET Gainers: Lipella Pharmaceuticals ( LIPO ) +48% . ThermoGenesis Holdings ( THMO ) +34% . Genelux ( GNLX ) +14% . Homology Medicines ( FIXX ) +10% . Biora Therapeutics ( BIOR ) +7% . Losers: Esperi...
-- NUZYRA ® (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the Prior Year -- Continued Progress on the Rare Disease Nontuberculous Mycobacteria (NTM) & BARDA Project BioShield Anthrax Programs BOSTON, Ma...
2023-03-15 13:23:35 ET Paratek Pharmaceuticals ( NASDAQ: PRTK ) is scheduled to announce FY earnings results on Thursday, March 16th, before market open. The consensus EPS Estimate is -$0.94 (+23.0% Y/Y) and the consensus Revenue Estimate is $148.18M (+13.8% Y/Y). Over...
2023-03-15 11:30:26 ET Major earning expected before the bell on Thursday include: Cresco Labs ( OTCQX:CRLBF ) Dollar General ( DG ) Jabil ( JBL ) Hello Group ( MOMO ) Williams-Sonoma ( WSM ) For further details see: Notable earnings befor...
BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, March 16, 2023 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarte...
Summary Today, we are putting the spotlight on small biotech concern Cidara Therapeutics for the first time in more than a year and a half. The company has an impressive set of collaboration deals with larger drug firms and its first FDA approval is on the near-term horizon. An inve...
News, Short Squeeze, Breakout and More Instantly...
Paratek Pharmaceuticals Inc. Company Name:
PRTK Stock Symbol:
NASDAQ Market:
Paratek Pharmaceuticals Inc. Website:
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Paratek Pharmaceuticals Inc. (PRTK) is expected to report $-0.25 for Q3 2023
BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military ...